Pharmas and Biotechs Dominated in 2015—Will They Do It Again in 2016?
In my January 9 Cabot Wealth Advisory, I wrote about the three top performers of 2015. Today, I take a look at the next nine top performers of 2015.
NeoPhotonics (NPTN) 3.37 to +223%...
Read More
In my January 9 Cabot Wealth Advisory, I wrote about the three top performers of 2015. Today, I take a look at the next nine top performers like NeoPhotonics (NPTN), 5 Intra-Cellular Therapies (ITCI) and others.
Read More
A person stops being a chump by finding a successful investing system that makes sense to them and then following it!
Read More
Today’s Daily Alert brings a new low-priced pharmaceutical stock idea from The CHEAP Investor.
“ArQule, Inc. (ARQL) engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate tivantinib (ARQ 197) is an inhibitor of c-Met...
Read More